Global /United States /Healthcare /Biotechnology /SEER
chevron_leftBack
Seer, Inc. logo

Seer, Inc.

SEER
NASDAQ: SEER Delayed
1.88USD -2.6%
As of 14 June 2026, Seer, Inc. has a market cap of $106.07M USD, ranking #25110 globally and #3874 in the United States. It ranks #2246 in the Healthcare sector, and #431 in the Biotechnology industry.
Global Rank
25110
Country Rank
3874
Sector Rank
2246
Industry Rank
431
Key Stats
Market Cap
$106.07MUSD
Enterprise Value
-$56.46MUSD
Revenue (TTM)
$16.58MUSD
EBITDA (TTM)
-$71.89MUSD
Net Income (TTM)
-$73.6MUSD
PS Ratio
6.4
PB Ratio
0.4
Company Profile
Country (HQ)
Sector
Healthcare
Industry
Biotechnology
CEO
Omid Farokhzad open_in_new
Employees
124
Founded
2017
IPO
04 Dec 2020
Website
seer.bio open_in_new
warningChart data may be delayed
1d 1w 1m 3m 6m 1y
-2.6% -5.1% 13% 0.5% -18% -4.1%

News

Loading...

SEER Analyst Forecasts

Loading...

Markets

Exchange Ticker Price
NASDAQ
MIC: XNAS
PRIMARY
SEER
Seer Inc Ordinary Shares - Class A
ISIN: US81578P1066
Shares Out.:
55.316M1 Shares Float: 31.234M2
TV:
SA:
YF:
GF:
NQ:
BA:
MS:
1.88 USD
1Market cap is calculated using shares outstanding.
2Float shares are publicly tradable shares, excluding insider-held stock.

About Seer, Inc.

Seer, Inc., a life sciences company, develops and commercializes products to decode the biology of the proteome to improve human health in the United States, China, Australia, Europe, Israel, Japan, and South Africa. The company offers Proteograph Product Suite, an integrated solution, which includes proprietary engineered nanoparticles, consumables, automation instrumentation, and data analysis software to perform proteomic analysis to provide a solution that can be incorporated by nearly any lab for research use only. The company also offers Proteograph ONE, a third-generation assay; Proteograph DIRECT, which provides an automated approach for direct digestion of samples for bottom-up LC-MS proteomic analysis; and Proteograph Analysis Suite, a data analytics software suite designed to support quality control, data management, and interpretation of Proteograph output which is currently offered as a cloud-based solution. It markets and sells its products for research use only, which cover academic institutions, life sciences, and research laboratories, as well as biopharmaceutical and biotechnology companies for non-diagnostic and non-clinical purposes. The company was formerly known as Seer Biosciences, Inc. and changed its name to Seer, Inc. in July 2018. Seer, Inc. was incorporated in 2017 and is headquartered in Redwood City, California.

Similar Companies

Industry: Biotechnology (United States)
Name
Market Cap diff.
PE
AMGN
$182.42B
172K%
23.9
GILD
$159.92B
151K%
19.0
NTRA
$27.6B
26K%
-
$26.3B
25K%
20.0
$25.03B
23K%
20.4
MRNA
$18.13B
17K%
-
Industry: Biotechnology (Global)
Name
Market Cap diff.
PE
ARGX
$47.84B
41.39B EUR
45K%
39.9
$44.84B
68.19T KRW
42K%
35.5
CSL
$42.36B
60.27B AUD
40K%
29.3
LONN
$42.3B
33.71B CHF
40K%
37.2
068270
$28.11B
42.76T KRW
26K%
43.8
BNTX
$25.69B
24K%
-
chevron_leftBack